Brief: Shanghai Junshi Biosciences Announces Acceptance Of Supplemental New Drug Application
19/07/2023 16:18
July 19 (Reuters) - Shanghai Junshi Biosciences Co Ltd
688180.SS :
* ACCEPTANCE OF SUPPLEMENTAL NEW DRUG APPLICATION FOR
TORIPALIMAB
AS FIRST-LINE TREATMENT OF ES-SCLC
* RECEIVED ACCEPTANCE NOTICE BY NATIONAL MEDICAL PRODUCTS
ADMINISTRATION OF CHINA FOR SUPPLEMENTAL NEW DRUG
Further company coverage: 688180.SS
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Shanghai Junshi Biosciences
See all newsBrief: Shanghai Junshi Biosciences Q3 Net Loss At 170.9 Million Yuan
Brief: Shanghai Junshi Biosciences Q3 Net Loss At 170.9 Million Yuan
Brief: Shanghai Junshi Biosciences Receives Supplemental Drug Approval From NMPA
Brief: Shanghai Junshi Biosciences's Shareholder Plans To Cut Stake
Brief: Shanghai Junshi Biosciences Gets NMPA Acceptance Notice Of Supplemental Application For Toripalimab